ATRA
Atara Biotherapeutics, Inc
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Best Biotech Stocks 2026 →
Atara Biotherapeutics (ATRA) Stock: Buy, Sell, or Hold?
$7.93
-0.30 (-3.65%)
▼
5d:
-0.38%
30d:
-17.05%
90d:
-1.98%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (86%)
Quality Score
51/100
Position
OVERSOLD
30-Day Fair Range
$8.19 – $9.39
Position: OVERSOLD
Forward P/E & Valuation
5.1x
CHEAP
vs 12.5x historical avg
Wall Street Target
$13.67
+72.3% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$7.47 / $8.65
Trend: Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: ATRA shows conflicting indicators. Wait for confirmation before entering.
Get Alerted When ATRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$27.06
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$16.80
52.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ATRA is currently trading at $7.93, which is considered oversold relative to its 30-day fair value range of $8.19 to $9.39. From a valuation perspective, the stock is trading at a discount (Forward PE: 5.1) compared to its historical average (12.5). Remarkably, the market is currently pricing in an annual earnings decline of 25.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ATRA is in a downtrend. Immediate support is located at $7.47, while resistance sits at $8.65. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: ATRA scores 70/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $13.67 (+72.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ATRA is in a downtrend. Immediate support is located at $7.47, while resistance sits at $8.65. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: ATRA scores 70/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $13.67 (+72.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$8.19 -
$9.39
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
85.7%
Trading Range & Key Levels
30-Day Trading Range
$8.19 -
$9.39
Current vs Trading Range
OVERSOLD
Support Level
$7.47
Resistance Level
$8.65
Current Trend
Downtrend
Technical data as of
Nov 12, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (70/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.6%)
- BULLISH: Trading 72.3% below Wall St target ($13.67)
- WARNING: Composite score 51/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
5.13
Wall Street Target
$13.67
(+72.3%)
Revenue Growth (YoY)
-64.6%
Valuation Discount vs History
-25.7% cheaper
PE vs Historical
5.1 vs 12.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-25.7%
(market-implied from PE analysis)
1-Year Target
$7.14
(-10%)
2-Year Target
$6.42
(-19%)
3-Year Target
$5.78
(-27%)
3-Yr Target (if PE normalizes)
(PE: 5→13)
$14.08
(+78%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.1 to 12.5
Stabilization Target:
$19.31
(+143.5%)
PE Expansion Potential:
+143.5%
Share ATRA Analysis
Share this live ATRA analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (ATRA)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Oct 14, 2026
Daily AI digest
AI Retail Discussion Summary:
Atara Biotherapeutics' Tab-cel® Biologics License Application for tabelecleucel has been accepted by the FDA.
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 9:16 PM ET
Data refreshes hourly during market hours. Next update: 10:16 PM
Data refreshes hourly during market hours. Next update: 10:16 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
25 analysts |
$261 | 38 SELL |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 41 HOLD |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$32 | 42 HOLD |
|
SNDX
Syndax Pharmaceuticals I… |
STRONG BUY
12 analysts |
$35 | 58 HOLD |
|
ACHV
Achieve Life Sciences Inc |
STRONG BUY
12 analysts |
$14 | 56 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive ATRA Research Pages
